JP2014533235A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533235A5 JP2014533235A5 JP2014505291A JP2014505291A JP2014533235A5 JP 2014533235 A5 JP2014533235 A5 JP 2014533235A5 JP 2014505291 A JP2014505291 A JP 2014505291A JP 2014505291 A JP2014505291 A JP 2014505291A JP 2014533235 A5 JP2014533235 A5 JP 2014533235A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- amino acid
- pharmaceutical composition
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 41
- 229920001184 polypeptide Polymers 0.000 claims 40
- 102000004196 processed proteins & peptides Human genes 0.000 claims 40
- 125000003275 alpha amino acid group Chemical group 0.000 claims 29
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 230000002159 abnormal effect Effects 0.000 claims 16
- 210000001519 tissue Anatomy 0.000 claims 16
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 claims 14
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 claims 14
- 230000001225 therapeutic effect Effects 0.000 claims 14
- 210000004072 lung Anatomy 0.000 claims 12
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 10
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 10
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 8
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 8
- 230000008021 deposition Effects 0.000 claims 8
- 210000002744 extracellular matrix Anatomy 0.000 claims 8
- 210000002950 fibroblast Anatomy 0.000 claims 8
- 230000035755 proliferation Effects 0.000 claims 8
- RAVVEEJGALCVIN-AGVBWZICSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RAVVEEJGALCVIN-AGVBWZICSA-N 0.000 claims 6
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 4
- 101001043352 Homo sapiens Lysyl oxidase homolog 2 Proteins 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 4
- 102000004889 Interleukin-6 Human genes 0.000 claims 4
- 108090001005 Interleukin-6 Proteins 0.000 claims 4
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 4
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 claims 4
- 102100021948 Lysyl oxidase homolog 2 Human genes 0.000 claims 4
- 101710092489 Protein kinase 2 Proteins 0.000 claims 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- 206010052779 Transplant rejections Diseases 0.000 claims 4
- 206010069351 acute lung injury Diseases 0.000 claims 4
- 229940124630 bronchodilator Drugs 0.000 claims 4
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 4
- 230000004927 fusion Effects 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 229940100601 interleukin-6 Drugs 0.000 claims 4
- 210000000651 myofibroblast Anatomy 0.000 claims 4
- 229940044551 receptor antagonist Drugs 0.000 claims 4
- 239000002464 receptor antagonist Substances 0.000 claims 4
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 108010006654 Bleomycin Proteins 0.000 claims 2
- 241000283690 Bos taurus Species 0.000 claims 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 2
- 102000012432 Collagen Type V Human genes 0.000 claims 2
- 108010022514 Collagen Type V Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 108010008165 Etanercept Proteins 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 2
- 102000004559 Interleukin-13 Receptors Human genes 0.000 claims 2
- 108010017511 Interleukin-13 Receptors Proteins 0.000 claims 2
- 108090000978 Interleukin-4 Proteins 0.000 claims 2
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 2
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 claims 2
- 101710141394 MAP kinase-activated protein kinase 2 Proteins 0.000 claims 2
- 208000037273 Pathologic Processes Diseases 0.000 claims 2
- 102000001708 Protein Isoforms Human genes 0.000 claims 2
- 108010029485 Protein Isoforms Proteins 0.000 claims 2
- 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 229960004308 acetylcysteine Drugs 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 208000038016 acute inflammation Diseases 0.000 claims 2
- 230000006022 acute inflammation Effects 0.000 claims 2
- 208000030961 allergic reaction Diseases 0.000 claims 2
- 230000000202 analgesic effect Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000001078 anti-cholinergic effect Effects 0.000 claims 2
- 229960005475 antiinfective agent Drugs 0.000 claims 2
- 239000004599 antimicrobial Substances 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 229960001561 bleomycin Drugs 0.000 claims 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 2
- 239000000168 bronchodilator agent Substances 0.000 claims 2
- 229960004436 budesonide Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 230000006020 chronic inflammation Effects 0.000 claims 2
- 238000013270 controlled release Methods 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 230000004069 differentiation Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 108091007231 endothelial receptors Proteins 0.000 claims 2
- 230000007613 environmental effect Effects 0.000 claims 2
- 229960000403 etanercept Drugs 0.000 claims 2
- 229960001469 fluticasone furoate Drugs 0.000 claims 2
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 claims 2
- 229960000289 fluticasone propionate Drugs 0.000 claims 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 208000016361 genetic disease Diseases 0.000 claims 2
- 239000003862 glucocorticoid Substances 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 102000006495 integrins Human genes 0.000 claims 2
- 108010044426 integrins Proteins 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 230000003902 lesion Effects 0.000 claims 2
- 150000002617 leukotrienes Chemical class 0.000 claims 2
- 229940127212 long-acting beta 2 agonist Drugs 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000002297 mitogenic effect Effects 0.000 claims 2
- 229960002744 mometasone furoate Drugs 0.000 claims 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 230000009054 pathological process Effects 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 150000003815 prostacyclins Chemical class 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 229940127211 short-acting beta 2 agonist Drugs 0.000 claims 2
- 229960003310 sildenafil Drugs 0.000 claims 2
- 230000000391 smoking effect Effects 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 2
- 239000012730 sustained-release form Substances 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 102000003810 Interleukin-18 Human genes 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161474370P | 2011-04-12 | 2011-04-12 | |
| US61/474,370 | 2011-04-12 | ||
| PCT/US2012/033368 WO2012142320A2 (en) | 2011-04-12 | 2012-04-12 | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014533235A JP2014533235A (ja) | 2014-12-11 |
| JP2014533235A5 true JP2014533235A5 (enExample) | 2015-06-11 |
| JP6031510B2 JP6031510B2 (ja) | 2016-11-24 |
Family
ID=47006527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014505291A Expired - Fee Related JP6031510B2 (ja) | 2011-04-12 | 2012-04-12 | 異常な線維芽細胞増殖及び細胞外マトリックスの沈着を特徴とする疾患、症状又はプロセスを予防又は治療する組成物及び方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9642888B2 (enExample) |
| EP (1) | EP2696888B1 (enExample) |
| JP (1) | JP6031510B2 (enExample) |
| KR (1) | KR101862291B1 (enExample) |
| CN (3) | CN108014340A (enExample) |
| AU (1) | AU2012242768B2 (enExample) |
| BR (1) | BR112013026313A8 (enExample) |
| CA (2) | CA2832910C (enExample) |
| DK (1) | DK2696888T3 (enExample) |
| ES (1) | ES2711670T3 (enExample) |
| HK (1) | HK1255005A1 (enExample) |
| MX (1) | MX359516B (enExample) |
| RU (1) | RU2620066C2 (enExample) |
| SG (2) | SG194135A1 (enExample) |
| WO (1) | WO2012142320A2 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1976828B1 (en) | 2005-12-29 | 2016-12-21 | Celtaxsys, Inc. | Diamine derivatives as inhibitors of leukotriene a4 hydrolase |
| DK2155228T3 (da) | 2007-01-10 | 2014-07-07 | Purdue Research Foundation | Polypeptidinhibitorer af HSP27-kinase og anvendelser herfor |
| JP5703466B2 (ja) | 2007-08-07 | 2015-04-22 | パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | キナーゼ阻害薬およびその使用 |
| AU2009324661A1 (en) * | 2008-12-10 | 2011-07-07 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| WO2011017132A2 (en) * | 2009-07-27 | 2011-02-10 | Purdue Research, Foundation | Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration |
| US20130115256A1 (en) * | 2010-05-24 | 2013-05-09 | Cynthia Lander | Methods for treating or preventing vascular graft failure |
| US9890200B2 (en) | 2011-04-12 | 2018-02-13 | Moerae Matrix, Inc. | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| SG194135A1 (en) | 2011-04-12 | 2013-11-29 | Matrix Inc Moerae | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
| FR2976587B1 (fr) * | 2011-06-20 | 2015-04-03 | Basf Beauty Care Solutions F | Methode de dosage in vitro par technique immunologique |
| WO2013134636A1 (en) | 2012-03-09 | 2013-09-12 | Purdue Research Foundation | Compositions and methods for delivery of kinase inhibiting peptides |
| EP2914269B1 (en) * | 2012-10-31 | 2020-07-29 | Galecto Biotech AB | Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis |
| US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
| ES2864862T3 (es) | 2013-03-12 | 2021-10-14 | Celltaxis Llc | Métodos de inhibición de la leucotrieno A4 hidrolasa |
| MX2015011677A (es) | 2013-03-14 | 2016-07-08 | Celtaxsys Inc | Inhibidores de leucotrieno a4 hidrolasa. |
| CN105473133A (zh) | 2013-04-30 | 2016-04-06 | 欧缇托匹克公司 | 干粉制剂及使用方法 |
| SG11201607627RA (en) * | 2014-03-14 | 2016-10-28 | Moerae Matrix Inc | Compositions and methods for preventing or treating chronic lung allograft dysfunction and idiopathic pulmonary fibrosis |
| US10336788B2 (en) * | 2014-04-17 | 2019-07-02 | Moerae Matrix, Inc. | Inhibition of cardiac fibrosis in myocardial infarction |
| KR20170083063A (ko) * | 2014-11-17 | 2017-07-17 | 모레 매트릭스 인코포레이티드 | 이상 섬유모세포 증식 및 세포외 기질 침착을 특징으로 하는 질병, 질환, 또는 과정의 예방 또는 치료용 조성물 및 방법 |
| US10087225B2 (en) | 2015-01-08 | 2018-10-02 | Moerae Matrix, Inc. | Formulation of MK2 inhibitor peptides |
| RU2017135072A (ru) | 2015-03-12 | 2019-04-10 | Мори Матрикс, Инк. | Применение пептидсодержащих композиций ингибитора mk2 для лечения немелкоклеточного рака легкого |
| US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
| EP3684338A4 (en) | 2017-09-22 | 2021-06-23 | Otitopic Inc. | DRY POWDER COMPOSITIONS WITH MAGNESIUM STEARATE |
| CN107987128B (zh) * | 2017-11-17 | 2019-06-11 | 广东医科大学 | 一种功能多肽及其在制备防治肺纤维化药物中的应用 |
| CN112437663A (zh) * | 2018-05-17 | 2021-03-02 | 开动疗法公司 | 用β型糖原合酶激酶3抑制剂治疗特发性肺纤维化 |
| US10898484B2 (en) | 2018-05-31 | 2021-01-26 | Celltaxis, Llc | Method of reducing pulmonary exacerbations in respiratory disease patients |
| CN110108883A (zh) * | 2018-10-27 | 2019-08-09 | 广州呼吸健康研究院 | 用于筛选与靶治疗ards患者的msc精准医学的标志物组合 |
| CN109406795A (zh) * | 2018-11-20 | 2019-03-01 | 昆明医科大学 | 一种轻型脑外伤的血清分子诊断标记物及应用 |
| WO2021040673A1 (en) * | 2019-08-26 | 2021-03-04 | Alain Martin | Methods for the treatment of chronic hypoxemia and inhibiting lung fibrosis in patients with pulmonary fibrosis with and without copd |
| USD958124S1 (en) | 2019-12-16 | 2022-07-19 | Samsung Electronics Co., Ltd. | Television receiver |
| USD978094S1 (en) | 2019-12-27 | 2023-02-14 | Samsung Electronics Co., Ltd. | Television receiver |
| WO2021146662A1 (en) * | 2020-01-17 | 2021-07-22 | Muhammed Majeed | Therapeutic compositions and methods for pulmonary fibrosis |
| CN112386682B (zh) * | 2020-02-12 | 2022-12-06 | 王斌 | 纤连蛋白在制备治疗新型冠状病毒肺炎药物中的应用 |
| WO2021202031A1 (en) * | 2020-03-30 | 2021-10-07 | Figene, Llc | Peptides and adjuvants for augmentation of fibroblast therapy for coronavirus |
| WO2021202032A1 (en) * | 2020-04-01 | 2021-10-07 | Figene, Llc | Fibroblast mediated expansion and augmentation of immune regulatory cells for treatment of acute respiratory distress syndrome (ards) |
| EP4138916A4 (en) * | 2020-04-21 | 2024-04-17 | Remodeless CV Ltd. | NEW THERAPY FOR ACUTE LUNG TISSUE INJURY |
| USD989017S1 (en) | 2020-12-03 | 2023-06-13 | Samsung Electronics Co., Ltd. | Television receiver |
| USD989726S1 (en) | 2020-12-03 | 2023-06-20 | Samsung Electronics Co., Ltd. | Television receiver |
| CN116391041A (zh) * | 2020-12-03 | 2023-07-04 | 江苏恒瑞医药股份有限公司 | 一种含抗结缔组织生长因子抗体的药物组合物 |
| WO2022147172A1 (en) * | 2020-12-30 | 2022-07-07 | Briotech, Inc. | Methods and compositions of aqueous hypobromous acid for the treatment and prevention of inflammatory conditions |
| US20220296645A1 (en) * | 2021-03-22 | 2022-09-22 | Spiritus Therapeutics, Inc. | Diagnostic and therapeutic uses of compositions comprising purified, enriched potent exosomes containing disease-based and therapy based signature cargo |
| CN113440431A (zh) * | 2021-08-02 | 2021-09-28 | 山西锦波生物医药股份有限公司 | 重组ⅲ型人源化胶原蛋白在头皮护理中的用途及包含其的头皮护理产品 |
| CN116262112A (zh) * | 2021-12-14 | 2023-06-16 | 南京安吉生物科技有限公司 | 一种雾化吸入用融合多肽制剂及其制备方法和应用 |
| WO2023134764A1 (zh) | 2022-01-14 | 2023-07-20 | 上海翰森生物医药科技有限公司 | 含吡啶多环类衍生物、其制备方法和应用 |
| CN114522221B (zh) * | 2022-02-28 | 2024-04-19 | 中国人民解放军陆军特色医学中心 | 分泌蛋白ctgf在用于制备治疗急性肺损伤药物中的应用 |
| WO2023178169A2 (en) * | 2022-03-15 | 2023-09-21 | Anemoi Biotech Holdings, Inc. | Compositions and methods for treating the pathophysiology of severe viral infection |
| CN116421704A (zh) * | 2023-02-20 | 2023-07-14 | 成都佩德生物医药有限公司 | 多肽pd-dp-005在制备治疗肺部疾病药物中的应用及其药物 |
| CN116789751B (zh) * | 2023-08-22 | 2023-11-17 | 中国农业大学 | 预防和/或治疗纤维化疾病的多肽及其应用 |
| CN117577330B (zh) * | 2024-01-15 | 2024-04-02 | 北京大学 | 预测非酒精性脂肪性肝病肝纤维化程度的装置及存储介质 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1521000A (en) | 1975-06-13 | 1978-08-09 | Syntex Puerto Rico Inc | Inhalation device |
| US4192309A (en) | 1978-09-05 | 1980-03-11 | Syntex Puerto Rico, Inc. | Inhalation device with capsule opener |
| US4227522A (en) | 1978-09-05 | 1980-10-14 | Syntex Puerto Rico, Inc. | Inhalation device |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| NL192564C (nl) | 1982-10-08 | 1997-10-03 | Glaxo Group Ltd | Inrichting voor het toedienen van medicamenten aan patiënten. |
| EP0211595B1 (en) | 1985-07-30 | 1991-11-13 | Glaxo Group Limited | Devices for administering medicaments to patients |
| JPH05963A (ja) | 1990-04-13 | 1993-01-08 | Toray Ind Inc | ポリペプチド類組成物 |
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
| AU4115693A (en) | 1992-04-24 | 1993-11-29 | Sri International | In vivo homologous sequence targeting in eukaryotic cells |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| CN1048254C (zh) | 1993-12-09 | 2000-01-12 | 托马斯杰弗逊大学 | 用于将预定的改变引入靶基因中的化合物 |
| US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| CA2367131C (en) | 1999-04-05 | 2007-07-03 | Solomon S. Steiner | Methods for fine powder formation |
| EP2280004B1 (en) | 1999-06-29 | 2016-04-20 | MannKind Corporation | Pharmaceutical formulations comprising insulin complexed with a diketopiperazine |
| MXPA04010560A (es) * | 2002-04-25 | 2005-08-15 | Scripps Research Inst | Tratamiento y prevencion de condiciones pulmonares. |
| PL218992B1 (pl) * | 2002-07-19 | 2015-02-27 | Abbott Biotech Ltd | Neutralizujące o wysokim powinowactwie izolowane ludzkie przeciwciało anty-TNFα, zastosowanie tego przeciwciała, kryształ zawierający ludzkie przeciwciało anty-TNFα i preparat zawierający ten kryształ |
| ES2365617T3 (es) * | 2003-11-25 | 2011-10-07 | Virginia Tech Intellectual Properties, Inc. | Composición para su consumo en animales y método para reducir la actividad de map quinasa. |
| JP2007537296A (ja) * | 2004-05-14 | 2007-12-20 | アボット・ラボラトリーズ | 治療薬としてのキナーゼ阻害薬 |
| DK1786784T3 (da) | 2004-08-20 | 2011-02-14 | Mannkind Corp | Katalyse af diketopiperazinsyntese |
| KR20070057829A (ko) | 2004-08-23 | 2007-06-07 | 맨카인드 코포레이션 | 포스포디에스테라아제 5형의 억제제의 폐 전달 |
| CN104436170B (zh) | 2004-08-23 | 2018-02-23 | 曼金德公司 | 用于药物输送的二酮哌嗪盐 |
| CN101227918A (zh) * | 2005-04-29 | 2008-07-23 | 加州大学评议会 | 治疗以炎症反应为特征的病理的肽和肽模拟物 |
| AU2006290227B2 (en) | 2005-09-14 | 2012-08-02 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
| KR20080096809A (ko) | 2006-02-22 | 2008-11-03 | 맨카인드 코포레이션 | 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법 |
| TW200817047A (en) * | 2006-04-03 | 2008-04-16 | Teva Pharma | Drug microparticles |
| DK2155228T3 (da) * | 2007-01-10 | 2014-07-07 | Purdue Research Foundation | Polypeptidinhibitorer af HSP27-kinase og anvendelser herfor |
| US8063094B2 (en) * | 2007-02-08 | 2011-11-22 | Boehringer Ingelheim International Gmbh | Anti-cytokine heterocyclic compounds |
| US20080282320A1 (en) | 2007-05-11 | 2008-11-13 | Denovo Andrew | Security Compliance Methodology and Tool |
| JP5703466B2 (ja) * | 2007-08-07 | 2015-04-22 | パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | キナーゼ阻害薬およびその使用 |
| US20110017340A1 (en) * | 2007-12-21 | 2011-01-27 | Cabot Corporation | Syntactic Foam Compositions, Pipelines Insulated with Same, and Method |
| KR20170001756A (ko) * | 2008-10-20 | 2017-01-04 | 모레 매트릭스 인코포레이티드 | 유착 치료 또는 예방용 폴리펩티드 |
| AU2009324661A1 (en) * | 2008-12-10 | 2011-07-07 | Purdue Research Foundation | Cell-permeant peptide-based inhibitor of kinases |
| US20130115256A1 (en) * | 2010-05-24 | 2013-05-09 | Cynthia Lander | Methods for treating or preventing vascular graft failure |
| SG194135A1 (en) | 2011-04-12 | 2013-11-29 | Matrix Inc Moerae | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition |
-
2012
- 2012-04-12 SG SG2013075031A patent/SG194135A1/en unknown
- 2012-04-12 CA CA2832910A patent/CA2832910C/en not_active Expired - Fee Related
- 2012-04-12 EP EP12771584.5A patent/EP2696888B1/en not_active Not-in-force
- 2012-04-12 CN CN201711403446.9A patent/CN108014340A/zh active Pending
- 2012-04-12 DK DK12771584.5T patent/DK2696888T3/en active
- 2012-04-12 CN CN201280027012.2A patent/CN104302310A/zh active Pending
- 2012-04-12 KR KR1020137029996A patent/KR101862291B1/ko not_active Expired - Fee Related
- 2012-04-12 SG SG10201604560TA patent/SG10201604560TA/en unknown
- 2012-04-12 ES ES12771584T patent/ES2711670T3/es active Active
- 2012-04-12 WO PCT/US2012/033368 patent/WO2012142320A2/en not_active Ceased
- 2012-04-12 JP JP2014505291A patent/JP6031510B2/ja not_active Expired - Fee Related
- 2012-04-12 US US13/445,759 patent/US9642888B2/en not_active Expired - Fee Related
- 2012-04-12 RU RU2013150249A patent/RU2620066C2/ru not_active IP Right Cessation
- 2012-04-12 MX MX2013011771A patent/MX359516B/es active IP Right Grant
- 2012-04-12 CA CA3042808A patent/CA3042808A1/en not_active Abandoned
- 2012-04-12 AU AU2012242768A patent/AU2012242768B2/en not_active Ceased
- 2012-04-12 BR BR112013026313A patent/BR112013026313A8/pt not_active Application Discontinuation
- 2012-04-12 CN CN201910892185.4A patent/CN111110850A/zh active Pending
-
2017
- 2017-04-04 US US15/478,950 patent/US20190022169A1/en not_active Abandoned
-
2018
- 2018-11-06 HK HK18114121.3A patent/HK1255005A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013150249A (ru) | Композиции и способы профилактики или лечения заболеваний, состояний или процессов, характеризуемых аберрантной пролиферацией фибробластов и отложением внеклеточного матрикса | |
| Chen et al. | Therapeutic strategies for targeting IL-33/ST2 signalling for the treatment of inflammatory diseases | |
| US8536303B2 (en) | Polypeptide inhibitors of HSP27 kinase and uses therefor | |
| CN103476933B (zh) | 白介素1受体的拮抗剂 | |
| JP2018501201A5 (enExample) | ||
| JP6725447B2 (ja) | Ｉｌ−４および／またはｉｌ−１３のそれぞれの受容体への結合を阻害することによる特定の障害の予防または治療のための方法 | |
| US20090263389A1 (en) | Use of TGF-Beta Antagonists to Treat or to Prevent Chronic Transplant Rejection | |
| EP2961426B1 (en) | Treatment of central nervous system disorders by intranasal administration of immunoglobulin g | |
| RU2017121090A (ru) | Композиции и способы для профилактики или лечения заболеваний, состояний или процессов, характеризующихся аберрантной пролиферацией фибробластов и накоплением внеклеточного матрикса | |
| KR20170029576A (ko) | 골형성단백질의 치료적 용도 | |
| JP2017528454A5 (enExample) | ||
| RU2017110093A (ru) | Композиции и способы для профилактики или лечения заболеваний, состояний или процессов, характеризующихся аберрантной пролиферацией фибробластов и накоплением внеклеточного матрикса | |
| CN115786270A (zh) | 工程化的巨噬细胞及其在治疗纤维化疾病中的应用 | |
| JP2004500844A (ja) | Ｔｗｅａｋアゴニストおよび血管形成因子を使用する、新血管新生を促進するための方法 | |
| JP2017509633A5 (enExample) | ||
| CN106075401A (zh) | 白介素35在制备治疗自身免疫性皮肤病药物中的用途和治疗药物以及IL‑35‑Fc融合蛋白 | |
| JP6757667B2 (ja) | Ｃｄ２８を介したシグナル伝達を阻害する短ペプチドによる炎症性疾病の症候の軽減 | |
| CN117186239A (zh) | 融合蛋白及其应用 | |
| TW201918259A (zh) | 基於胃泌酸調節素類似物glp-1r/gcgr雙靶點激動劑多肽治療特發性肺間質纖維化 | |
| CN105079780B (zh) | 一种特异结合trb3的多肽在治疗腹主动脉瘤中的应用 | |
| JP6261617B2 (ja) | 嚢胞性腎疾患の処置に使用されるリンパ管新生を誘発する作用物質 | |
| CN108295242B (zh) | 用于预防和/或治疗银屑病药物组合物、cd317胞外段蛋白的应用 | |
| CN117209612A (zh) | 融合蛋白及其应用 | |
| Pradhan et al. | Molecular targets for promoting wound healing in diabetes | |
| Liu et al. | Muscarinic acetylcholine receptor antagonist darifenacin protects against pulmonary fibrosis through ERK/NF-κB/miR-21 pathway |